Drug Profile
Pegfilgrastim biosimilar - Emcure Pharmaceuticals
Alternative Names: Pegylated apofilgrastim biosimilar - Emcure; Pegylated filgrastim biosimilar - Emcure; Pegylated G-CSF biosimilar - Emcure; Pegylated rhG-CSF biosimilar - EmcureLatest Information Update: 25 Nov 2021
Price :
$50
*
At a glance
- Originator Emcure Pharmaceuticals
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 21 Oct 2013 Launched for Neutropenia in India (SC)